Is Neurogene Inc (NGNE) overvalued? · rev $925.0K
Neurogene Inc (NGNE) is a biotechnology company listed on US.
This page asks whether Neurogene Inc (NGNE) looks expensive on cached numbers — not a short thesis.
Latest reported NGNE revenue for 2024-12-31 was $925.0K. Net income was -$75.1M. NGNE currently screens at market cap $286.5M.
NGNE currently screens at market cap $286.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NGNE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NGNE stock page for the full model, not this heading.
Not investment advice.